Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era.
We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 microg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of <or=2 microg/ml.
Guinea
Jesús
J
Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain. jguineaortega@yahoo.es
Recio
Sandra
S
Peláez
Teresa
T
Torres-Narbona
Marta
M
Bouza
Emilio
E
D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology*; D001230:Aspergillus / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D024881:Drug Resistance, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000592:standards; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole